MedTech Innovator January 2021 Newsletter
Letter from the CEO
Signs are pointing to 2021 shaping up to be a GREAT year for medtech. Right out of the gate, CMS granted my wish from last month’s newsletter, finalizing the MCIT rule, providing accelerated Medicare coverage for FDA Breakthrough devices. This is a win-win-win, reducing a major reimbursement risk factor for innovators & investors, and a HUGE win for patients who gain earlier access to innovative technologies. If you aren’t thinking about Breakthrough designation, you should be.
Funding and M&A activity in 2021 is promising. This month alone, our portfolio companies raised over $160 million. In context, our portfolio raised $600M for all of 2020,which was itself a great year. There has been a flurry of January M&A activity, including 2 acquisitions in our portfolio. Notably, BardyDx has an exit multiple at 19x revenues, according to an insider’s LinkedIn post- great news for investors & innovators. Strong comps are important.
SVB reported encouraging data in their 2020 Healthcare Investments & Exits report. $17B in new capital was raised by VC funds. By my personal tally, healthcare-focused VC’s have raised over $3B in fresh capital this January alone. That’s a lot of dry powder for innovators. Also good- total Device and HealthTech investments were up for the year. Disappointing- Device Series A was down (again). I believe there is a huge opportunity. If you’re interested in Device Series A investing, please reach out to me at my LinkedIn below.
Want proof of the opportunity ahead in 2021? We already have over 1,100 applications to our US program. Our Road Tour pitch events begin in February. If you are an investor or an industry executive, read below about how you can participate in what one of our partners described as “the most productive day in my career.”
Here’s to a great 2021. I hope to see you on our (virtual) Road Tour!
Paul Grand, CEO, MedTech Innovator
connect with me on Twitter & LinkedIn
News & Updates
Sign up to Judge in the MedTech Innovator 2021 Virtual Road Tour
“the most productive day in my career” — past judge
We’re not kidding with that quote. Our Road Tour pitch events have been described by our judges as “the first day I can remember never looking at my email or cell phone” and “the most productive day in my career”. These are tightly organized partnering sessions where world class industry judges will meet with the top startups and scaleups from our 2021 applicant pool. Startups get feedback and judges gain insights from peers and other experts.
Judges at each event include up to 100 investors, providers, customers, KOL’s, and senior executives from our partners at world-class medtech companies such as Johnson & Johnson, Olympus, Nipro, Gore, Baxter, Edwards Lifesciences, Dexcom, Aasahi Intecc, Maxim Integrated, Fujikura, Jabil and others. Historically, participation has resulted in investment, recruitment of advisors, and partnerships, among other outcomes.
If you are a business development representative, investor, payer or provider interested in serving as a judge, then please email us at events@medtechinnovator.org.
Upcoming Pitch Event Dates & Themes
Feb. 17 – Patient Monitoring / Telehealth
Feb. 18 – ENT / Behavioral Health / Sleep Medicine
Mar. 3 – Next-Gen Surgical
Mar. 8 – Cardiology / Cardiovascular / Robotics (part of #LAMedTechWeek)
Mar. 17 – Endocrinology / Diabetes / Metabolism
Mar. 18 – POC Diagnostics / Laboratory Medicine
Mar. 31 – GI / Renal / Neurology
Apr. 1 – Biomaterials / Sensors / Health IT / Digital Health
Apr. 14 – Digital Therapeutics / Chronic Disease Management
Apr. 15 – Infectious Disease / Respiratory / Critical Care
Apr. 28 – Pain Medicine / Orthopedics / Vascular / Interventional
Apr. 29 – Oncology / OB-GYN / Ophthalmology
May 6 – Mid-Stage Companies (raising series C or later)
Supporting Promising Medtech Firms:
Interview with Paul Grand, CEO of MedTech Innovator
EXCERPT: Medgadget: How do you anticipate that the COVID-19 pandemic will affect the Medtech landscape, and which medical technologies do you see emerging as the most important within the next ten years?
Paul Grand: COVID-19 has raised awareness of the importance of the Medtech sector, and I believe we’ll see a significant uptick in investor interest as a result. The pandemic has introduced systemic changes in how healthcare technology is developed and delivered, from executing clinical studies to the diagnosis, treatment, and monitoring of patients. I believe the genie is out of the bottle, and these changes are permanent. Read the full article here.
Upcoming Events & Deadlines
MedTech Color Pitch Competition
Application Deadline: Feb 5
Portfolio News
|
|
|
Thank You to our 2021 Sponsors
From first hand experience, we can definitively say that our corporate partners are among the most innovative companies in the world. If you are interested in working with these leaders and best-in-class innovators, please reach out to us. The largest life science accelerator in the world wants to partner with you in 2021!
 |
 |
 |
 |
 |
